Prostate Health Index




Test Mnemonic

PHI

CPT Codes

  • 84153 - QTY (1)

Aliases

  • PHI
  • Prostate Health Index, Serum

Includes

  • Total PSA

Performing Laboratory

LabCorp


Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
1 mLSerumSST (Gold) FrozenPatients should not be collected within six weeks after prostatic biopsy or immediately after digital rectal examination (DRE), prostatic massage, or transrectal ultrasound (TRUS). Separate specimens must be submitted when multiple tests are ordered. Separate serum from cells within 3 hours of collection and transfer to standard aliquot tube and freeze.

Alternate Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
1 mLSerumNo additive (Red) FrozenPatients should not be collected within six weeks after prostatic biopsy or immediately after digital rectal examination (DRE), prostatic massage, or transrectal ultrasound (TRUS). Separate specimens must be submitted when multiple tests are ordered. Separate serum from cells within 3 hours of collection and transfer to standard aliquot tube and freeze.

Minimum Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
0.7 mL     

Stability

Environmental Condition Description
Refrigerated24 hours
Frozen5 months (3x freeze/thaw cycles)
Ambient3 hours

Days Performed

Mon - Sat

Turnaround Time

4 - 6 days

Methodology

Name Description
Immunoassay (IA) 

Reference Range

PHI PSA, Serum
Sex Age From Age To Type Range Range Unit
       0.0 - 3.9 ng/mL 

Special Info

If reflex testing is performed, additional charges apply. If Total PSA is between 4.0 and 10.0 ng/mL, free PSA and p2PSA will be performed. Patients should not be collected within six weeks after prostatic biopsy or immediately after digital rectal examination (DRE), prostatic massage, or transrectal ultrasound (TRUS). Separate specimens must be submitted when multiple tests are ordered.

Clinical Info

This Beckman Coulter Access Hybritech PSA assay is indicated for the measurement of serum PSA in conjunction with digital rectal examination (DRE) as an aid in the detection of prostate cancer in men aged 50 years or older. Low Beckman Coulter PHI scores are associated with a lower probability of prostate cancer on biopsy, and higher scores are associated with an increased probability of prostate cancer on biopsy. The choice of an appropriate Beckman Coulter PHI score to be used in guiding clinical decision-making may vary for each patient and may depend in part on other clinically important factors or on family history of disease. Values obtained with different assays should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. It should be noted that a PSA range of 4 to 10 ng/mL using Hybritech calibration corresponds to a PSA range of 3.1 to 7.8 ng/mL using WHO calibration.

Clinical Limitation

This assay does not provide serial monitoring; it is intended for one-time use only.